Share Repurchase Program Initiated by Cooper Companies (NASDAQ:COO)

Cooper Companies (NASDAQ:COO) announced that its board has authorized a share buyback program on Wednesday, September 9th, RTT News reports. The company plans to repurchase $3.00 billion in shares. This repurchase authorization allows the medical device company to buy up to 22.7% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its shares are undervalued.

Cooper Companies Trading Down 0.5%

Cooper Companies stock opened at $53.91 on Friday. The company has a quick ratio of 0.78, a current ratio of 1.22 and a debt-to-equity ratio of 0.23. Cooper Companies has a 52 week low of $51.01 and a 52 week high of $89.83. The company has a market capitalization of $10.51 billion, a price-to-earnings ratio of 18.40, a price-to-earnings-growth ratio of 1.45 and a beta of 0.82. The stock has a 50-day moving average price of $71.62 and a 200 day moving average price of $69.70.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.03. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. The company had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.10 billion. During the same quarter in the prior year, the company earned $0.49 EPS. Cooper Companies’s quarterly revenue was up .5% on a year-over-year basis. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Sell-side analysts anticipate that Cooper Companies will post 4.53 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on COO shares. Wells Fargo & Company set a $61.00 target price on Cooper Companies and gave the stock an “equal weight” rating in a research note on Thursday. William Blair lowered shares of Cooper Companies from an “outperform” rating to a “market perform” rating in a research note on Thursday. Robert W. Baird set a $61.00 price target on shares of Cooper Companies and gave the stock a “neutral” rating in a report on Thursday. BNP Paribas Exane lowered their price objective on shares of Cooper Companies from $95.00 to $92.00 and set an “outperform” rating for the company in a research note on Monday, June 8th. Finally, UBS Group dropped their price objective on shares of Cooper Companies from $75.00 to $66.00 and set a “neutral” rating on the stock in a report on Thursday. Five investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $71.47.

Cooper Companies News Roundup

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Cooper reported adjusted fiscal Q3 earnings of $1.15 per share, ahead of the approximately $1.11–$1.12 consensus, with earnings up from $0.49 a year earlier. Cost controls and continued fertility-related growth helped offset weakness elsewhere. Cooper Companies Bets on Fertility Growth Despite Weakness in CooperVision
• Positive Sentiment: The board authorized an additional $1 billion of repurchases, bringing the total buyback authorization to $3 billion. The program could support per-share earnings and signal management believes COO shares are undervalued. Cooper Outlines Q4 EPS and Adds to Buyback Authorization
• Neutral Sentiment: Cooper completed a strategic review but chose not to pursue a sale or separate transaction for CooperSurgical. Keeping the business preserves its fertility-growth opportunity, but investors had apparently anticipated a potential deal or value-unlocking action. Cooper Cos. Stock Drops After Soft Outlook and No Deal
• Negative Sentiment: Revenue rose only about 1% to $1.066 billion, missing the roughly $1.10 billion consensus. U.S. channel destocking and inventory reductions pressured CooperVision, raising concerns about near-term demand and sales momentum. COO Q3 Earnings Top Estimates, Revenues Miss on Destocking
• Negative Sentiment: Management reduced fiscal 2026 earnings guidance to $4.51–$4.55 per share and issued fourth-quarter guidance of $1.05–$1.09, below prior expectations. The weaker outlook triggered multiple analyst downgrades and price-target cuts, including from Baird, UBS, JPMorgan and William Blair.
• Negative Sentiment: Law firms have announced securities-fraud investigations connected with the post-earnings decline. These notices are often promotional, but they add to negative investor sentiment and potential legal uncertainty. Securities Fraud Investigation Into Cooper Companies Announced

About Cooper Companies

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.